REDWOOD CITY, Calif., April 23, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that several abstracts have been accepted for presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2014 in Chicago, IL.
OncoMed will present new clinical data from its ongoing studies, including the Phase 1b study of demcizumab (OMP-21M18, anti-DLL4) in non-small cell lung cancer (NSCLC), the Phase 1/2 PINNACLE trial of OMP-59R5 (anti-Notch 2/3) in small-cell lung cancer (SCLC) and the Phase 1 trial of OMP-54F28 (FZD8-Fc) in patients with advanced solid tumors. The list of abstracts and timing of the presentations is provided below.
Read more: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=841935
This guest article is by Sean Duffy, CEO and Co-Founder, Omada Health
When Erica Rogers left the vascular business in 1999, carotid artery stenting was The Next Big Thing for interventional cardiologists. It only made sense, since as many as half of all strokes are caused by a narrowing of the primary arteries that run through the neck to the head, and cardiologists had experience with a somewhat similar procedure in narrowed heart vessels.
Health-tech startup Omada Health promises to help people with health issues change their behavior. And it’s starting out with a program to help diabetes sufferers.
Via Wall Street Journal:
Balaji Srinivasan, who was hired as a general partner by Andreessen Horowitz to help the firm move into new areas, has spearheaded the firm’s first major foray into health-care investing with a $23 million Series B round for digital therapy companyOmada Health, Tim Hay reports for VentureWire. Though Andreessen has backed several consumer-facing health technology companies, the funding for Omada was the first double-digit venture capital round for a company with clinically proven, prescription-based products, and it’s Andreessen’s first board seat at such a company.
OncoMed Presents Data on Multiple Anti-Cancer Stem Cell Programs at American Association for Cancer Research Annual Meeting
REDWOOD CITY, Calif. April 7, 2014 - OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical- stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced data from an oral presentation and eight poster presentations at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA April 5-9, 2014. The research presented at AACR highlighted OncoMed’s drug discovery platforms along with preclinical and biomarker discoveries on its clinical-stage product candidates and several emerging product candidates. A brief summary of each presentation is provided below.